Jeffrey Bluestone is stepping down from the CEO role at Sonoma Biotherapeutics, a regulatory T cell company he co-founded six years ago.
He'll be replaced by Stephen Dilly, who previously led RNAi therapy manufacturer Codexis ...
↧